# Treatment of Malignant Tumors With NK Cell

> **NCT05143125** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen University General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Malignancy

## Interventions

- **BIOLOGICAL:** Decitabine combined with NK cell infusion

## Key facts

- **NCT ID:** NCT05143125
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-05
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143125, "Treatment of Malignant Tumors With NK Cell". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05143125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*